Cargando…
miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling
MicroRNAs (miRNAs) have been identified as critical modulators of cell proliferation and growth, which are the major causes of cancer progression including hepatocellular carcinoma (HCC). Our previous miRNA microarray data have shown that miR-330-5p was always upregulated in HCC. However, the accura...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249243/ https://www.ncbi.nlm.nih.gov/pubmed/30464168 http://dx.doi.org/10.1038/s41389-018-0097-8 |
_version_ | 1783372703008292864 |
---|---|
author | Xiao, Shuai Yang, Mengyuan Yang, Hao Chang, Ruimin Fang, Feng Yang, Lianyue |
author_facet | Xiao, Shuai Yang, Mengyuan Yang, Hao Chang, Ruimin Fang, Feng Yang, Lianyue |
author_sort | Xiao, Shuai |
collection | PubMed |
description | MicroRNAs (miRNAs) have been identified as critical modulators of cell proliferation and growth, which are the major causes of cancer progression including hepatocellular carcinoma (HCC). Our previous miRNA microarray data have shown that miR-330-5p was always upregulated in HCC. However, the accurate role of miR-330-5p in HCC is still uncertain. Here, we report that miR-330-5p expression is upregulated in HCC tissues and cell lines, and is associated with tumor size, tumor nodule number, capsule formation and Tumor Node Metastasis (TNM) stage in HCC patients. Overexpression of miR-330-5p promotes proliferation and growth of HCC cells in vitro and in vivo, while miR-330-5p knockdown has the inverse effect. Moreover, using miRNA databases and dual luciferase report assay, we find miR-330-5p directly binds to the 3′-untranslated region (3′-UTR) of Sprouty2 (SPRY2). Then we find the novel biofunctional role of SPRY2 inactivation in promoting HCC progression. Finally, we confirm that miR-330-5p suppresses SPRY2 to promote proliferation via mitogen-activated protein kinases (MAPK)/extracellular regulated kinase (ERK) signaling in HCC. Taken together, our findings demonstrate the critical role of miR-330-5p in promoting HCC progression via targeting SPRY2 to activate MAPK/ERK signaling, which may provide a novel and promising prognostic marker and therapeutic target for HCC. |
format | Online Article Text |
id | pubmed-6249243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-62492432018-11-26 miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling Xiao, Shuai Yang, Mengyuan Yang, Hao Chang, Ruimin Fang, Feng Yang, Lianyue Oncogenesis Article MicroRNAs (miRNAs) have been identified as critical modulators of cell proliferation and growth, which are the major causes of cancer progression including hepatocellular carcinoma (HCC). Our previous miRNA microarray data have shown that miR-330-5p was always upregulated in HCC. However, the accurate role of miR-330-5p in HCC is still uncertain. Here, we report that miR-330-5p expression is upregulated in HCC tissues and cell lines, and is associated with tumor size, tumor nodule number, capsule formation and Tumor Node Metastasis (TNM) stage in HCC patients. Overexpression of miR-330-5p promotes proliferation and growth of HCC cells in vitro and in vivo, while miR-330-5p knockdown has the inverse effect. Moreover, using miRNA databases and dual luciferase report assay, we find miR-330-5p directly binds to the 3′-untranslated region (3′-UTR) of Sprouty2 (SPRY2). Then we find the novel biofunctional role of SPRY2 inactivation in promoting HCC progression. Finally, we confirm that miR-330-5p suppresses SPRY2 to promote proliferation via mitogen-activated protein kinases (MAPK)/extracellular regulated kinase (ERK) signaling in HCC. Taken together, our findings demonstrate the critical role of miR-330-5p in promoting HCC progression via targeting SPRY2 to activate MAPK/ERK signaling, which may provide a novel and promising prognostic marker and therapeutic target for HCC. Nature Publishing Group UK 2018-11-21 /pmc/articles/PMC6249243/ /pubmed/30464168 http://dx.doi.org/10.1038/s41389-018-0097-8 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Xiao, Shuai Yang, Mengyuan Yang, Hao Chang, Ruimin Fang, Feng Yang, Lianyue miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling |
title | miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling |
title_full | miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling |
title_fullStr | miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling |
title_full_unstemmed | miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling |
title_short | miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling |
title_sort | mir-330-5p targets spry2 to promote hepatocellular carcinoma progression via mapk/erk signaling |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249243/ https://www.ncbi.nlm.nih.gov/pubmed/30464168 http://dx.doi.org/10.1038/s41389-018-0097-8 |
work_keys_str_mv | AT xiaoshuai mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling AT yangmengyuan mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling AT yanghao mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling AT changruimin mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling AT fangfeng mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling AT yanglianyue mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling |